This conference would simply not be possible without the ongoing and dedicated support
of our industry sponsors and exhibitors.
Click on the logos below to find out more about these organisations
whose sponsorship is helping to bring your annual industry conference to life.
PLATINUM PARTNERS
The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Our mission is simple – To create a future worth living for patients worldwide, every day. Around 3.4 million patients with this disease worldwide regularly undergo dialysis treatment and every 0.6 seconds Fresenius Medical Care provide a dialysis treatment somewhere on the globe.
We care for more than 342,000 patients in our global network of over 4,000 dialysis clinics. At the same time, we operate 45 production sites on all continents, providing dialysis products such as dialysis machines, dialyzers and related disposables. Fresenius Medical Care has been developing and producing dialysis products for more than four decades.
The Fresenius Medical Care family employs around 120,000 people across 50 countries, who are instrumental in supporting over 50 million dialysis treatments annually.
Locally, our ANZ team supports dialysis products and services to public and private hospitals for patients with chronic or acute kidney failure. We are also one of the largest private dialysis providers, caring for patients across a network of 24 dialysis clinics as well as home therapies programs.
Our global and local strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality.
BRONZE PARTNERS
Find out more at www.boehringer-ingelheim.com.au and www.lilly.com.au
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Twentynine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines.
Founded in 1896, the Roche Group is headquartered in Basel, Switzerland, and is active in over 100 countries. In 2016 Roche employed more than 94,000 people worldwide and invested CHF 9.9 billion in research and development, including almost AUD 37 million in pharmaceuticals in Australia. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
Roche’s pharmaceutical division in Australia is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to about 40 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.
With our ethos of CHANGING TOMORROW™, Astellas is committed to exploring therapeutic areas in which there is a vital need for treatments that improve and lengthen patients’ lives. We’re not in the business of making ‘me too’ medicines. We strive to develop therapies that are first-in-class and best-in-class treatments that offer patients and their doctors genuinely new options for improving care.
Through the support of our parent company, Alkem Laboratories Limited, we are focussed on a robust pipeline forecasted for the next decade. Pharmacor has proven success in launching first generics to market such as Cinacalcet, Rasagiline, Ezetimibe, Gliclazide and Paracetamol sustained release.
With global presence in over 50 countries, Alkem proudly operates 21 manufacturing facilities for both active material and finished products, and a passionate Research and Development team of over 500 scientists, in India and the United States. New ventures are presently being explored at Alkem’s subsidiaries, Enzene Biosciences, Maharashtra, and Norac Pharma, California, which offer biosimilars and controlled substance manufacturing, respectively.
Together, we are building a legacy in providing greater access to a wide range of therapeutic categories of medicine in Australia and around the world. Our mission at Pharmacor is ensuring Australians receive affordable, timely access to essential medicines without premium prices as Pharmacor proudly supplies over 100 medicines through PBS today, and will continue to grow in the future.
For more information about who we are, visit www.alkemlabs.com and www.pharmacor.com.au.
UPDATE COURSE THEME SPONSORS
Advances in Nephrology in 2020 Theme Sponsor
Transplantation Theme Sponsor
With our ethos of CHANGING TOMORROW™, Astellas is committed to exploring therapeutic areas in which there is a vital need for treatments that improve and lengthen patients’ lives. We’re not in the business of making ‘me too’ medicines. We strive to develop therapies that are first-in-class and best-in-class treatments that offer patients and their doctors genuinely new options for improving care
General Nephrology Theme Sponsor
We are a leader in the treatment of iron deficiency and iron deficiency anaemia where our products treat over half a million Australian patients annually.
Located in Melbourne and head-quartered in Switzerland, we are a mid-sized pharmaceutical company actively engaged with patients advocates healthcare professionals and policy makers.
Vifor Pharma is proud to sponsor local medical education and invest in local research and development to help patients to lead better, healthier lives.
AWARD SPONSOR
EPOSTER LOUNGE SPONSOR
KHA Clinical Science Award and the 2020 ANZSN and KHA Environmental Research Award
With 1.5 million Australians unaware they have the early signs of kidney disease, early detection continues to be a key driver for Kidney Health Australia, with a focus on awareness raising activities targeting those at risk, as well as educating the primary care sector on the earlier diagnosis and treatment of kidney disease.
Research into kidney disease also continues to be a key focus, with the organization working with the clinical and research community to support treatment improvements and innovations so that one day, every Australian can enjoy good kidney health.
For more information visit kidney.org.au
This site uses cookies. Find out more about cookies and how you can refuse them.